

Choroidal thickness in patients with central serous chorioretinopathy (CSC) and myopia

Published: 28-08-2018

Last updated: 11-04-2024

To demonstrate choroidal thickness of emmetropic and myopic CSC patients to be significantly different.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Retina, choroid and vitreous haemorrhages and vascular disorders
Study type	Observational non invasive

Summary

ID

NL-OMON45973

Source

ToetsingOnline

Brief title

CSC and myopia

Condition

- Retina, choroid and vitreous haemorrhages and vascular disorders

Synonym

Central Serous Chorioretinopathy

Research involving

Human

Sponsors and support

Primary sponsor: Oogziekenhuis Rotterdam

Source(s) of monetary or material Support: Rotterdamse Stichting Blindenbelangen

Intervention

Keyword: Central Serous Chorioretinopathy, Choroid thickness, Myopia

Outcome measures

Primary outcome

Subfoveal choroidal thickness.

Secondary outcome

Vascular changes in the choroid.

Axila length of the eye.

Study description

Background summary

Central serous chorioretinopathy (CSC) is a common form of macular degeneration characterized by the presence of subretinal fluid (SRF), most often found subfoveally. In some cases there is spontaneous resolution of SRF, but if not and left untreated it will result in irreversible vision loss. Although CSC is a common disease, at present our knowledge on the pathogenesis of CSC is scarce. Of particular interest appears to be a subgroup of patients with CSC and myopic refraction. Possibly, the thinner choroid in myopia is potentially protective for developing CSC.

Study objective

To demonstrate choroidal thickness of emmetropic and myopic CSC patients to be significantly different.

Study design

Cross-sectional, observational study.

Study burden and risks

This is an observational study. Risks are negligible.

Contacts

Public

Oogziekenhuis Rotterdam

Schiedamse Vest 180
Rotterdam 3011 BH
NL

Scientific

Oogziekenhuis Rotterdam

Schiedamse Vest 180
Rotterdam 3011 BH
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Age * 18 years

Informed consent

A history of CSC

Myopia

Exclusion criteria

None.

Study design

Design

Study type: Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Basic science

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 02-04-2019

Enrollment: 30

Type: Actual

Ethics review

Approved WMO

Date: 28-08-2018

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register

CCMO

ID

NL65899.078.18